HGH vs MK-677: Growth-Hormone Axis Comparison | Regena

HGH (recombinant somatropin) is a 191-amino-acid recombinant protein identical to native human growth hormone. It acts directly at the growth-hormone receptor as the endpoint of the growth-hormone axis, bypassing the entire hypothalamic-pituitary secretagogue cascade.

MK-677 (ibutamoren) is a non-peptide small molecule that acts as an orally active agonist at the growth-hormone-secretagogue receptor. It drives the endogenous growth-hormone axis to release GH through the natural pituitary pathway — producing an endogenous, pulsatile GH signal rather than an exogenous flat signal.

HGH acts at the growth-hormone receptor directly and drives IGF-1 production through the natural hepatic-axis downstream signalling. The pharmacological signature is a direct, dose-dependent exogenous GH signal.

MK-677 acts at the ghrelin receptor and drives endogenous GH release from the pituitary. The signature is a sustained but still pulsatile GH release pattern, with the natural axis preserved.

HGH has a short pharmacokinetic half-life (approximately 2–3 hours) and is typically administered by subcutaneous research injection at daily or sub-daily cadences.

MK-677 has a reported half-life of approximately 24 hours, is dosed orally once daily in published research, and produces a sustained ghrelin-axis stimulus.

HGH is used in research protocols requiring direct exogenous growth-hormone exposure — GH-receptor pharmacology, receptor-signalling studies and any design where controlling the GH signal directly is the requirement.

MK-677 is used in research protocols requiring sustained endogenous GH-axis activation with the natural pituitary axis intact — chronic-exposure metabolic, body-composition or sleep-architecture research models where preserving the endogenous pulsatile release is part of the design.

Both HGH (Somatropin) and MK-677 ship from Regena only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds are published on the Regena lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena COA.

HGH ships as a lyophilised recombinant protein; hold at 2–8 °C, avoid freeze-thaw cycling, and reconstitute with bacteriostatic water for a refrigerated in-use window. MK-677 ships as a solid or oral-solution research kit; storage conditions are cool and dry, protected from light. HGH is substantially more sensitive to handling than MK-677.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both HGH (Somatropin) and MK-677 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose HGH when the protocol requires direct exogenous GH-receptor activation or a controlled exogenous GH signal for pharmacology or receptor studies. Researchers choose MK-677 when the protocol requires sustained oral endogenous GH-axis activation, when preserving the natural pituitary axis is part of the design, or when a chronic-exposure oral research tool is preferable to an injectable exogenous protein.

For multi-compound comparator studies, the Regena consultations team will reserve matched-batch inventory of both HGH (Somatropin) and MK-677 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both HGH (Somatropin) and MK-677 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on the Regena site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.